Article Information
History
- October 12, 2022.
Article Versions
- You are currently viewing Version 1 of this article (October 12, 2022 - 19:43).
- Version 2 (October 28, 2022 - 07:31).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Lampros Spiliopoulos1,*,
- Anna Irene Vedel Sørensen2,
- Peter Bager1,2,
- Nete Munk Nielsen1,3,
- Jørgen Vinsløv Hansen1,
- Anders Koch2,4,5,
- Inger Kristine Meder1,
- Poul Videbech7,
- Steen Ethelberg2,5 and
- Anders Hviid1,6
- 1Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen S, Denmark
- 2Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 2300 Copenhagen S, Denmark
- 3Focused Research Unit in Neurology, Department of Neurology, Hospital of Southern Jutland, University of Southern Denmark, 6200 Aabenraa, Denmark
- 4Department of Infectious Diseases, Rigshospitalet University Hospital, 2100 Copenhagen Ø, Denmark
- 5Department of Public Health, Global Health Section, University of Copenhagen, 1014 Copenhagen K, Denmark
- 6Pharmacovigilance Research Centre, Department of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen Ø, Denmark
- 7Centre for Neuropsychiatric Depression Research, Mental Health Centre Glostrup, 2600 Glostrup, Denmark and University of Copenhagen, Copenhagen, Denmark
- ↵*Correspondence to: Lampros Spiliopoulos (lmsp{at}ssi.dk)
Posted October 12, 2022.
Post-acute symptoms four months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study
